Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

Stopped early · Phase 2

Conditions studied: Coagulopathy

In brief

Phase 2a study to assess the safety and efficacy of IV infused spray-dried solvent/detergent -treated plasma (Resusix) when compared with an equal volume of plasma frozen within 24 hours after phlebotomy (FP24) in patients with liver disease who are actively bleeding or who require prophylaxis for surgical bleeding

Key facts

Study ID
NCT03700723
Run by
Entegrion, Inc.
People needed
4
Starts
2018-12-14
Expected to finish
2020-04-15
Last updated by the study team
2021-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.